Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) Servier and (b) the MHRA about making Vorasidenib available to clinically suitable brain tumour patients in the UK under the Early Access to Medicines Scheme

The Secretary of State and the Department have had no specific discussions with Servier about making Vorasidenib available to clinically suitable brain tumour patients in the United Kingdom under the Early Access to Medicines Scheme (EAMS).

The Medicines and Healthcare Products Regulatory Agency (MHRA) has also not had any specific discussions with the Secretary of State regarding Vorasidenib. The MHRA has not issued a scientific opinion for Vorasidenib under EAMS but should an application for this be received, the MHRA will consider this accordingly.